Study of metformin effects in mTOR/S6Ks signal transduction pathway in lung cancer cells

Ana Paula Morelli, Tharcisio Citrangulo Tortelli Junior, Isadora Carolina Betim Pavan, Fernando Riback Silva, Roger Chammas, Fernando Moreira Simabuco.

Abstract
Over the past few years, the mTOR signal transduction pathway has been associated to the control of body energy balance, acting as a sensor of the amount of nutrients available or a trigger for the expense or storage of energy. The S6Ks proteins have shown an important role in the mTOR signaling, working as effectors of this signaling pathway, although there are still questions not answered. Among the diseases related to obesity, as well as to the control or dysfunction of the mTOR/S6Ks pathway, cancer may be highlighted, whose incidence in obese is clearly higher. Metformin has been used in the treatment of type II diabetes, but many reports in the literature indicate its importance also as a drug against cancer. This research project aimed to study the effects of metformin treatment in the mTOR/S6Ks signaling pathway in A549 lung cancer cells. Our results show that metformin is able to reduce the mTOR pathway signaling even after treatment of cells with a low dose of cisplatin, which may induce lung cancer resistance.

Key words:
Cancer, metformin, mTOR.

Introduction
Lung adenocarcinoma is one of the main causes of cancer mortality worldwide and its prognosis remains poor, with a five-year survival rate of 15%. Therefore, the effective prevention and treatment have a high importance for this type of cancer. The metformin, a biguanide drug used in the treatment of diabetes type II, known to decrease blood glucose by mean liver and mitochondrial metabolism, has been shown to also reduce cancer effects¹. This was discovered after previous epidemiological studies on patients with diabetes who were treated with metformin, which presented lower cancer mortality than patients who received other drugs. Besides, the prevalence of diabetes in newly diagnosed cancer patients is near 20%, suggesting a bidirectional association between these two diseases².

Metformin is also able to increase the citotoxicity effects of chemotherapy treatments of cancer, including the cisplatin in different lung cancer cell lines, but the molecular mechanisms are still unclear. Given the important role of the mTOR/S6K pathway in diseases related to metabolism such as obesity, diabetes and cancer, a relationship of the positive effects of metformin in cancer and this pathway may be characterized.

For this purpose, we inviestigated whether A549 lung cancer cells in a combination of treatments between cisplatin and metformin present a modulation of the mTOR/S6Ks signaling pathway.

Results and Discussion
Firstly, A549 cells were cultured in a 6 well plate and treated with metformin 10 μM, cisplatin 10 μM or metformin plus cisplatin for 72 hours. We found that metformin is able to decrease the phosphorylation of S6K1 and S6 proteins and thus decrease the signaling of mTOR pathway. Moreover, metformin was able to improve the effects of cisplatin, since the increased of the mTOR/S6Ks signaling by cisplatin was reversed by the combination with metformin (Figure 1).

According to previous studies³, the cell line A549 has a nonsense LKB1 mutation at codon 37. The LKB1 gene inactivation does not sensitize small cell lung cancer to mTOR inhibitor in vitro. Acta Pharmacologica Sinica,v.36, p. 1107-1112, 2015.

Conclusions
In this study we have observed a reduction of the mTOR/S6K signaling pathway after treatment with metformin in A549 lung cancer cell line. This reduction was also achieved after a low dose of cisplatin treatment, which may induce lung cancer resistance. Besides, this effect has been characterized independent of the fact that A549 are not functional for LKB1/AMPK pathway, which is known to inhibit mTOR/S6Ks signaling pathway.

Acknowledgement
This project was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and collaborations of Faculdade de Medicina do Estado de São Paulo (FMUSP)

Figures

1. Regulation of S6K1 and S6, components of the mTOR signaling pathway, after treatment with cisplatin (CIS), metformin (MET) or their combination (CISMET).

References

DOI: 10.19146/pibic-2016-51413